Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer
Evaluation of the Efficacy and Safety of TQB3616 Capsules Combined with Hormonal Therapy in a Phase II Clinical Trial for Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor-Resistant, HR-Positive, HER2-Negative Recurrent/Metastatic Breast Cancer.
Breast Cancer
DRUG: TQB3616 capsule+Fulvestrant Injection
Objective Response Rate, The proportion of patients achieving complete response and partial response among the total evaluable cases., Baseline up to 12 months
Progression Free Survival, Progression Free Survival (PFS) is defined as the length of time from the start of treatment until the disease progresses or the patient dies from any cause., Baseline up to 12 months|Duration of Response, The time from the first assessment of the tumor as a complete response or partial response to the first occurrence of disease progression or death from any cause., Baseline up to 12 months|Disease Control Rate, The percentage of subjects with a complete response, partial response, or stable disease as determined by RECIST 1.1., Baseline up to 12 months|Clinical Benefit Rate, The percentage of subjects with a complete response, partial response, or stable disease for ≥24 weeks as determined by RECIST 1.1., From the first dose to complete response, partial response, or stable disease for ≥24 weeks|Overall Survival, The time from the start of initial treatment to death from any cause, Baseline up to 24 months|Adverse event (AE), Incidence and severity of adverse events, From the subject's signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
Evaluation of the Efficacy and Safety of TQB3616 Capsules Combined with Hormonal Therapy in a Phase II Clinical Trial for Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor-Resistant, HR-Positive, HER2-Negative Recurrent/Metastatic Breast Cancer.